BiotechTube

Fostamatinib disodium

Phase 3Recruiting
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Antibody Autoimmune Hemolytic Anemia

Conditions

Warm Antibody Autoimmune Hemolytic Anemia

Trial Timeline

Oct 30, 2019 → Apr 1, 2024

NCT ID
NCT04138927

About Fostamatinib disodium

Fostamatinib disodium is a phase 3 stage product being developed by Rigel Pharmaceuticals for Warm Antibody Autoimmune Hemolytic Anemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04138927. Target conditions include Warm Antibody Autoimmune Hemolytic Anemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT04138927Phase 3Recruiting
NCT02077192Phase 3Completed
NCT00798096Phase 2Completed

Competing Products

12 competing products in Warm Antibody Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
77
rituximab (Mabthera®) + PlaceboRochePhase 3
77
rilzabrutinibSanofiPhase 2
51
Isatuximab SAR650984SanofiPhase 2
51
parsaclisinib + placeboIncytePhase 3
74
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
49
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
60
APL-2Apellis PharmaceuticalsPhase 2
47
Obexelimab + ObexelimabZenas BioPharmaPhase 3
72
ANX005AnnexonPhase 2
47
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
44
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
69

Other Products from Rigel Pharmaceuticals

Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesApproved
77
Fostamatinib Disodium + PlaceboPhase 3
69
Fostamatinib DisodiumPhase 3
69
Fostamatinib + PlaceboPhase 3
69
Fostamatinib disodium + PlaceboPhase 3
69